Retinal vein thrombosis after infliximab (Remicade) treatment for Crohn’s disease

Puli, Srinivas R.; Benage, David D.
April 2003
American Journal of Gastroenterology;Apr2003, Vol. 98 Issue 4, p939
Academic Journal
No abstract available.


Related Articles

  • Infliximab for Crohn's disease. ROSE, VERNA L. // American Family Physician;12/1/1998, Vol. 58 Issue 9, p2175 

    Introduces the monoclonal antibody, infliximab (Remicade), use for the treatment of Crohn's disease. Mechanism of action; Clinical trials; Side effects.

  • First treatment approved for Crohn's disease.  // FDA Consumer;Nov/Dec98, Vol. 32 Issue 6, p3 

    Reports on the licensing of Remicade (infliximab), a treatment for Crohn's disease from Centocor Inc. Information on Crohn's disease; Composition of the product; Details on the clinical trials of the treatment; Side effects of the treatment.

  • A Breakthrough In Treating Crohn's Disease. Cerrato, Paul L. // RN;Nov98, Vol. 61 Issue 11, p92 

    Focuses on the United States Food and Drug Administration's approval of Infliximab (Remicade) for the treatment of Crohn's disease. How the genetically engineered antibody drug works; Adverse effects of the drug.

  • Crohn's disease.  // Geriatrics;Dec98, Vol. 53 Issue 12, p16 

    Announces that Infliximab (Remicade), an intravenous (IV) injectable chimeric Immunoglobulin Gamma (IgG) monoclonal antibody, was approved for the treatment of Crohn's disease. Recommended dose; Most common side effects.

  • Pneumocystis Jirovecii Pneumonia Complicating Treatment With Infliximab. Fahy, Ruairi J.; Diaz, Philip T. // Internet Journal of Pulmonary Medicine;2006, Vol. 6 Issue 2, p5 

    Blockade of TNF-a using tumor necrosis factor-a antibodies is used in the management of a number of chronic inflammatory diseases and is indicated for treatment of refractory Crohn's Disease. We report the development of Peumocystis Jirovecii (Carinii) pneumonia and acute respiratory failure in...

  • Remicade Approved for Children With Crohn's Disease.  // FDA Consumer;Jul/Aug2006, Vol. 40 Issue 4, p6 

    The article provides information on Remicade (infliximab), a drug approved by the U.S. Food and Drug Administration (FDA) to treat children with active Crohn's disease, a chronic inflammatory condition of the bowel that can be severely debilitating. Remicade is a genetically engineered...

  • Re: Triantafillidis et al.--Acute Idiopathic Pancreatitis Complicating Active Crohn's Disease: Favorable Response to Infliximab Treatment. Fefferman, David S.; Alsahli, Mazen; Lodhavia, Parag J.; Shah, Samir A.; Farrell, Richard J. // American Journal of Gastroenterology;Aug2001, Vol. 96 Issue 8, p2510 

    Presents a letter to the editor about a patient with Crohn's disease complicated by acute idiopathic pancreatitis that improved after treatment with infliximab.

  • Infliximab.  // Reactions Weekly;10/1/2011, Issue 1371, p21 

    The article describes the case of a 74-year-old man who developed seizure after treatment with infliximab for Crohn's disease.

  • Infliximab.  // Reactions Weekly;5/15/2010, Issue 1301, p29 

    The article describes the case of two men who developed fulminant legionellosis after being given infliximab as treatment for Crohn's disease.

  • Crohn's Disease. Lewis, Carol // FDA Consumer;Sep/Oct99, Vol. 33 Issue 5, p26 

    Provides information on Crohn's disease. Signs and symptoms; Treatment; Effectiveness of Remicade, a genetically engineered antibody; Diagnosis; Treatment; Diet.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics